Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents in a Commercial Claims Cohort of Individuals With Early-Phase Schizophrenia

Jose M. Rubio, MD^a,b,c,* ; Marko A. Mychaskiw, PhD^d ; Sangtaeck Lim, MPH^d ; Mark Suett, MD^e ; Yitong Wang, MS^f ; Marc Tian, PhD^f ; John M. Kane, MD^a,b,c

J Clin Psychiatry 2023;84(2):22m14604

https://youtu.be/BfEP40PLkHg

ABSTRACT

Objective: Long-acting injectable antipsychotic agents (LAIs) have improved clinical effectiveness and adherence versus oral antipsychotic agents (OAs); however, a minority of individuals with schizophrenia are treated with LAIs compared with OAs. This cohort study aimed to evaluate predictors of initiation of atypical LAIs among patients with newly diagnosed schizophrenia in the United States.

Methods: Using claims data from IBM MarketScan Commercial and Medicare Supplemental databases between January 1, 2013, and March 31, 2020, adults with first diagnosis of schizophrenia, ≥ 1 OA claim following diagnosis, and continuous benefits were identified. To evaluate predictors of LAI initiation, a Cox proportional hazard regression model per independent predictors and main outcome (ie, LAI initiation) was performed.

Results: Of 3,639 patients with early-phase schizophrenia, 369 (10%) had ≥ 1 LAI claim(s) after ≥ 1 OA claim(s). Several factors present prior to LAI initiation were significantly (P < .0001) predictive of LAI initiation: greater monthly OA switches (hazard ratio [95% CI]: 11.39 [7.01–18.51]), unsuccessful OA implementation (3.09 [2.39–3.98]), greater monthly schizophrenia-related hospitalizations (20.83 [14.22–30.51]), and greater monthly schizophrenia-related emergency department visits (4.13 [2.07–8.22]).

Conclusions: In this analysis of pharmacy claims records for patients with early-phase schizophrenia, results suggest that LAIs are used less frequently in the early phase than reported in later stages. Their initiation is often reactive to relapse or disease exacerbation, rather than proactive as a relapse-prevention tool for early-phase schizophrenia. These data highlight the underuse of LAIs, particularly in the early phase when they could make the most difference.

Continue Reading...

Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (41)

Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1(1):15067. PubMed CrossRef
Patel KR, Cherian J, Gohil K, et al. Schizophrenia: overview and treatment options. P&T. 2014;39(9):638–645. PubMed
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. PubMed CrossRef
Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005;17(3):137–140. PubMed CrossRef
López-Muñoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3):113–135. PubMed CrossRef
Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071. PubMed CrossRef
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. PubMed CrossRef
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. PubMed CrossRef
Lopez LV, Shaikh A, Merson J, et al. Accuracy of clinician assessments of medication status in the emergency setting: a comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol. 2017;37(3):310–314. PubMed CrossRef
Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404. PubMed CrossRef
Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693. PubMed CrossRef
Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–280. PubMed CrossRef
Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(suppl 14):27–30. PubMed
Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? antipsychotic response in first- vs second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036–1042. PubMed CrossRef
Taipale H, Tanskanen A, Correll CU, et al. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry. 2022;9(4):271–279. PubMed CrossRef
Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–1224. PubMed CrossRef
Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829. PubMed CrossRef
2019–2020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults. Florida Agency for Health Care Administration. The University of South Florida. 2020. https://floridabhcenter.org/adult-guidelines/2019-2020-florida-best-practice-psychotherapeutic-medication-guidelines-for-adults/
Lian L, Kim DD, Procyshyn RM, et al. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: a systematic review and meta-analysis. Early Interv Psychiatry. 2022;16(6):589–599. PubMed CrossRef
Pilon D, Joshi K, Tandon N, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619–629. PubMed CrossRef
Bareis N, Olfson M, Wall M, et al. Variation in psychotropic medication prescription for adults with schizophrenia in the United States. Psychiatr Serv. 2022;73(5):492–500. PubMed
Robinson DG, Subramaniam A, Fearis PJ, et al. Focused ethnographic examination of barriers to use of long-acting injectable antipsychotics. Psychiatr Serv. 2020;71(4):337–342. PubMed CrossRef
Weiden PJ, Roma RS, Velligan DI, et al. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015;76(6):684–690. PubMed CrossRef
Şahin OŞ, Mursalova Z, Gadimov S, et al. Predictors of long-acting injectable antipsychotic prescription at discharge in patients with schizophrenia and other psychotic disorders. Int Clin Psychopharmacol. 2021;36(5):251–256. PubMed CrossRef
Rubio JM, Taipale H, Tanskanen A, et al. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull. 2021;47(6):1611–1620. PubMed CrossRef
Gilbert JL, Nelson LA, Kriz CR, et al. Identifying predictors of primary adherence to second generation long-acting injectable antipsychotics following discharge from an acute inpatient psychiatry unit. Psychopharmacol Bull. 2019;49(2):8–16. PubMed
Üçok A, Yağcioğlu EA, Aydin M, et al. Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder. Int Clin Psychopharmacol. 2021;36(2):89–96. PubMed CrossRef
IBM Watson Health. IBM MarketScan Research Databases for life sciences researchers. Accessed March 8, 2022. https://www.ibm.com/downloads/cas/OWZWJ0QO
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. PubMed CrossRef
Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. PubMed CrossRef
Wei Y, Yan VKC, Kang W, et al. Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia. JAMA Netw Open. 2022;5(7):e2224163. PubMed CrossRef
Zichlin ML, Mu F, Leo S, et al. The impact of antipsychotic dose reduction on clinical outcomes and health care resource use among medicare patients with schizophrenia. Clin Drug Investig. 2021;41(10):853–863. PubMed CrossRef
West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995–1001. PubMed CrossRef
Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247. PubMed CrossRef
Keepers GA, Fochtmann LJ, Anzia JM, et al; (Systematic Review). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. PubMed CrossRef
Pelayo-Terán JM, Gajardo Galán VG, de la Ortiz-García de la Foz V, et al. Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). Eur Arch Psychiatry Clin Neurosci. 2017;267(4):315–323. PubMed CrossRef
Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. PubMed CrossRef
He H, Liu Q, Li N, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci. 2020;29:e91. PubMed CrossRef
Caroli F, Raymondet P, Izard I, et al. Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011;5:165–171. PubMed CrossRef
Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275–282. PubMed CrossRef
Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5):IN18031AH1C. PubMed CrossRef